Nucleocapsid Projects

Developing Inhibitors to Nucleocapsid RNA binding, dimerisation, phase separation

Funded by bayerische Forschungsstiftung - start 1.12.2020 - "Inhibiting COVID-19 N-Protein mediated infectivity" (AZ-1461-20C). Documents of the BFS are attached; Application attached

• Scientific - Nucleocapsid Protein (NP)
• Important results to the Nucleocapsid project - Results - Nuclapsid projects
• Tools (RNA, Protein, Inhibitors..) to run the project - Tools - Nucleocapsid Project
• Project administration - money, accounts, UR, BFS, etc. - Project AZ-1461-20C Administration

Längst group aims

1. RBD - RNA binding inhibitor screen
2. CTD - Inhibition of dimerisation
3. Identification of the PS
4. NP - inhibition of LLPS
5. NP-RNA assembly

Screen Inhibitors with Creoptix Wave (together with 2bind) NP - screen Creoptix WAVE

Wagner group

Development of an active S1 cDNA clone

NP phase separation cell line with RNA

2bind

Inhibitor screens - RNA binding inhibitors

Fraunhofer

Cellular inhibitor screen with the cDNA virus clone

LLPS in vivo inhibitors

LLPS in vitro inhibitors

Nucleocapsid a cell penetrating protein

NP - cell penetrating protein project

Project overview, impact

• Vaccine alternative, or potentially more efficient: RNA import, RNA stabilisation in the cell, efficient translation
• It may mean that also destroyed viruses may be problematic and infectious
• N-RNA Vaccine in a lipid nanoparticle: in case TL is more efficient
• Just an N-RNA spray for uptake in epithelia - as vaccine